The options for patients with locally advanced non-small cell lung cancer (NSCLC) who are not candidates for a standard definitive chemoradiotherapy regime are meagre. These are patients who are not fit for a chemoradiotherapy schedule of 66 Gy in 2 Gy fractions due to either tumour extent, resulting in excessive dose to the healthy tissue in the thorax, or with performance status not supporting seven weeks of intensive treatment.
The aim is to study the efficiency as well as the safety of a new treatment option of heterogeneously hypofractionated radiotherapy for patients with locally advanced NSCLC who are not candidates for standard, high-dose chemoradiotherapy, either due to excessive irradiation of normal tissue (defined as category A patients) or due to fragility of the patient (category B patients).
Histologically or cytological confirmed locally advanced, inoperable NSCLC.
Age ≥18 years.
Signed informed consent.
Performance status 0-2.
Prior radiotherapy to the thorax, unless there is no significant overlap of current treatment volumes with previous treatment fields.
Dose plan conforming to protocol planning criteria not possible.
Uncontrolled metastatic disease.
Other active malignant disease.
Danish Lung Cancer Group
Lead sponsor
Odense University Hospital
Collaborator
Rigshospitalet, Denmark
Collaborator
Vejle Hospital
Collaborator
Herlev Hospital
Collaborator
Aarhus University Hospital
Collaborator